Jeanne M. Palmer
机构：Mayo Clinic, WinnMed, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic in Florida · ORCID：0000-0002-2185-1504
发表论文 470 篇 · 总被引 11710 次 · h-index 45
代表论文
- Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy (2026 · American Journal of Hematology · 被引 6)
- Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial (2025 · Blood · 被引 4)
- Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents (2026 · American Journal of Hematology · 被引 2)
- CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients (2026 · Blood Cancer Journal · 被引 2)
- Association Between Transfusion Status, Hemoglobin Levels, and Patient‐Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis (2026 · Cancer Medicine · 被引 1)
- TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent (2026 · American Journal of Hematology · 被引 1)